Skip to content

US · AVTR · MEDICAL - INSTRUMENTS & SUPPLIES

Avantor, Inc. (AVTR) intrinsic value and stock valuation

$14.84as of 2026-11-21 · Mkt cap 9.19B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Avantor, Inc. DCF and intrinsic value

InvestorsCraft values AVTR with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from AVTR’s statements →

Avantor, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Radnor, PA 19087 avantorsciences.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$6.55B+0.5% 5y CAGRd
20152025
Net income
-$-530.2M
20152025
Free cash flow
$495M-10.6% 5y CAGRd
20152025
Total equity
$5.57B+15.8% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$6.55B$6.78B$6.97B$7.51B$7.39B
Operating income-$-246.2M$1.08B$696.4M$1.13B$972.2M
Net income-$-530.2M$711.5M$321.1M$686.5M$572.6M
EPSd-$-780.51K$1.04M$473.3K$1.01M$955K
Operating cash flow$623.8M$840.8M$870M$843.6M$953.6M
Capital expenditure-$-128.8M-$-148.8M-$-146.4M-$-133.4M-$-111.1M
Free cash flow$495M$692M$723.6M$710.2M$842.5M
Total assets$11.8B$12.1B$13B$13.5B$13.9B
Total debt$3.95B$4.06B$5.54B$6.29B$7.02B
Net debt$3.58B$3.79B$5.27B$5.91B$6.72B
Total equity$5.57B$5.96B$5.25B$4.86B$4.2B
Cash and short-term investments$365.4M$261.9M$262.9M$372.9M$301.7M
Income statement
20252024202320222021
Revenue$6.55B$6.78B$6.97B$7.51B$7.39B
Cost of revenue$4.41B$4.5B$4.6B$4.91B$4.88B
Gross profit$2.14B$2.28B$2.36B$2.6B$2.5B
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$1.6B$1.64B$1.51B$1.47B$1.53B
Other expenses$790.1M-$-446.6M$160.8M$0.00$0.00
Operating expenses$2.39B$1.19B$1.67B$1.47B$1.53B
Cost and expenses$6.8B$5.7B$6.27B$6.38B$6.41B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$169.8M$218.8M$284.8M$265.8M$217.4M
Depreciation and amortization$410.2M$405.5M$402.3M$405.5M$379.2M
Ebitda$138.7M$1.48B$1.1B$1.52B$1.35B
Operating income-$-246.2M$1.08B$696.4M$1.13B$972.2M
Total other income/expenses, net-$-195.1M-$-230.9M-$-285.9M-$-279.1M-$-219.2M
Income before tax-$-441.3M$853.9M$410.5M$851.1M$753M
Income tax expense$88.9M$142.4M$89.4M$164.6M$180.4M
Net income-$-530.2M$711.5M$321.1M$686.5M$572.6M
Weighted average shares outstanding$678M$680.3M$675.6M$650.9M$590.5M
Weighted average diluted shares outstanding$679.3M$681.9M$678.4M$679.4M$599.6M
Balance sheet
20252024202320222021
Cash and short-term investments$365.4M$261.9M$262.9M$372.9M$301.7M
Net receivables$1.07B$1.03B$1.15B$1.22B$1.22B
Inventory$818.2M$731.5M$828.1M$913.5M$872M
Total current assets$2.45B$2.15B$2.38B$2.66B$2.48B
Property, plant and equipment, net$766.8M$708.1M$737.5M$727M$705.5M
Goodwill and intangible assets$8.18B$8.9B$9.49B$9.79B$10.5B
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$9.34B$9.97B$10.6B$10.8B$11.4B
Total assets$11.8B$12.1B$13B$13.5B$13.9B
Accounts payable$741.7M$662.8M$625.9M$758.2M$755.1M
Short-term debt$30.8M$821.1M$259.9M$364.2M$45.2M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.38B$2.01B$1.48B$1.66B$1.45B
Long-term debt$3.92B$3.23B$5.28B$5.92B$6.98B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$4.85B$4.15B$6.24B$6.95B$8.25B
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$6.23B$6.16B$7.72B$8.61B$9.7B
Common stock$3.98B$3.94B$3.83B$3.79B$2.75B
Retained earnings$1.67B$2.2B$1.49B$1.17B$483.9M
Accumulated other comprehensive income (loss)-$-16.9M-$-184M-$-69M-$-100.3M-$-43.2M
Total equity$5.57B$5.96B$5.25B$4.86B$4.2B
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$3.95B$4.06B$5.54B$6.29B$7.02B
Net debt$3.58B$3.79B$5.27B$5.91B$6.72B
Cash flow statement
20252024202320222021
Net income-$-530.2M$711.5M$321.1M$686.5M$572.6M
Depreciation and amortization$410.2M$405.5M$402.3M$405.5M$379.2M
Stock-based compensation$46.4M$46.8M$40.5M$45.8M$50.7M
Change in working capital-$-198.9M$47.7M$16.6M-$-321.3M-$-114.5M
Accounts receivable$13.6M$45.9M$77M-$-45.2M-$-111.8M
Inventory-$-109.4M-$-18.5M$30.3M-$-112.5M-$-129.8M
Accounts payable$42.4M$59.6M-$-139.6M$15.6M$64.9M
Net cash provided by operating activities$623.8M$840.8M$870M$843.6M$953.6M
Investments in property, plant and equipment-$-128.8M-$-148.8M-$-146.4M-$-133.4M-$-111.1M
Acquisitions, net$0.00$0.00$0.00-$-20.2M-$-4.01B
Net cash used for investing activities-$-130.5M$438.9M-$-143.7M-$-109.6M-$-4.12B
Common stock issued$5.1M$0.00$0.00$0.00$967M
Common stock repurchased-$-80.7M-$-8.6M-$-13.7M-$-13.2M-$-25.8M
Dividends paid$0.00$0.00$0.00-$-32.4M-$-64.6M
Net cash used for financing activities-$-409.4M-$-1.28B-$-843.7M-$-648.7M$3.22B
Net change in cash$103.6M-$-23M-$-109.2M$69.8M$37.9M
Cash at end of period$368.3M$264.7M$287.7M$396.9M$327.1M
Operating cash flow$623.8M$840.8M$870M$843.6M$953.6M
Capital expenditure-$-128.8M-$-148.8M-$-146.4M-$-133.4M-$-111.1M
Free cash flow$495M$692M$723.6M$710.2M$842.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Avantor, Inc.

        Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample preparation kits, educational and microbiology products, clinical trial kits, peristaltic pumps, and various fluid handling tips. Beyond consumables, Avantor also supplies advanced equipment and instrumentation. This range includes filtration and virus inactivation systems, incubators, analytical devices, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. Complementing its product offerings, Avantor delivers a suite of crucial services. These encompass on-site laboratory and production support, clinical services, equipment maintenance, comprehensive procurement and sourcing solutions, and specialized biopharmaceutical material scale-up and development expertise.

        CEO
        Emmanuel Ligner
        Employees
        13.5K
        Beta
        0.94

        Explore

        Frequently asked questions

        What is the intrinsic value of Avantor, Inc. (AVTR)?

        Avantor, Inc. (AVTR) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is AVTR undervalued?

        AVTR trades at a price of $14.84 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.